>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Abercrombie & Fitch (ANF) upgraded to Buy from Neutral at UBS; tgt raised to $220
    • Agilon Health (AGL) upgraded to Neutral from Sell at Citigroup; tgt raised to $2.25
    • Bath & Body Works (BBWI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $48
    • Boot Barn Holdings (BOOT) upgraded to Buy from Neutral at UBS; tgt raised to $210
    • Burlington Stores (BURL) upgraded to Buy from Neutral at UBS; tgt raised to $360
    • Canadian Nat'l Rail (CNI) upgraded to Buy from Hold at Jefferies; tgt $120
    • Capri Holdings (CPRI) upgraded to Buy from Neutral at Citigroup; tgt raised to $29
    • Capri Holdings (CPRI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $28
    • C.H. Robinson (CHRW) upgraded to Outperform from Mkt Perform at Raymond James; tgt $123
    • Commercial Metals (CMC) upgraded to Neutral from Sell at UBS; tgt lowered to $54
    • Corebridge Financial (CRBG) upgraded to Buy from Hold at Deutsche Bank; tgt raised to $40
    • CSX (CSX) upgraded to Buy from Hold at Jefferies; tgt $37
    • CubeSmart (CUBE) upgraded to Hold from Sell at Deutsche Bank; tgt lowered to $45
    • Equitable Holdings (EQH) upgraded to Buy from Hold at Deutsche Bank; tgt raised to $58
    • Everest Group (EG) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt raised to $453
    • FTAI Aviation Ltd. (FTAI) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $190
    • Gap (GAP) upgraded to Neutral from Sell at UBS; tgt raised to $26
    • Gilead Sciences (GILD) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $113
    • Precision BioSciences (DTIL) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt $34
  • Downgrades:
    • Advanced Micro Devices (AMD) downgraded to Neutral from Buy at Goldman; tgt lowered to $129
    • AppFolio (APPF) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • Archer Aviation (ACHR) downgraded to Neutral from Overweight at JP Morgan; tgt raised to $9
    • Array Tech (ARRY) downgraded to Neutral from Positive at Susquehanna; tgt $7
    • BigCommerce (BIGC) downgraded to Underweight from Equal Weight at Barclays; tgt lowered to $7
    • Cemig (CIG) downgraded to Hold from Buy at HSBC Securities
    • Enterprise Products (EPD) downgraded to Peer Perform from Outperform at Wolfe Research
    • Hims & Hers Health (HIMS) downgraded to Sell from Neutral at Citigroup; tgt raised to $25
  • Others:
    • Agilon Health (AGL) initiated with a Hold at Needham
    • Amentum Holdings (AMTM) initiated with a Sector Perform at RBC Capital Mkts; tgt $24
    • BioNTech (BNTX) initiated with a Buy at Truist; tgt $172
    • Bright Minds Biosciences (DRUG) initiated with a Buy at H.C. Wainwright; tgt $85
    • Chord Energy (CHRD) initiated with an Equal-Weight at Morgan Stanley; tgt $158
    • Cingulate (CING) initiated with a Buy at ROTH MKM; tgt $12
    • Civitas Resources (CIVI) initiated with an Overweight at Morgan Stanley; tgt $64
    • CNX Resources (CNX) initiated with an Underweight at Morgan Stanley; tgt $29
    • Comstock (CRK) initiated with an Equal-Weight at Morgan Stanley; tgt $18
    • DT Midstream (DTM) initiated with an Equal Weight at Barclays; tgt $112
    • Enterprise Products (EPD) initiated with a Sector Perform at Scotiabank; tgt $33
    • Eton Pharmaceuticals (ETON) initiated with a Buy at B. Riley Securities; tgt $21
    • Evolent Health (EVH) initiated with a Buy at Needham; tgt $15
    • Expand Energy Corporation (EXE) initiated with an Overweight at Morgan Stanley; tgt $127
    • Instacart (CART) initiated with a Equal Weight at Wells Fargo; tgt $47

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • AVDL -25.5% (product revenue guidance), NEOG -4.4%, PSMT -3.2%, TLRY -2.9%, JEF -2.2%, WSC -1.8% (guidance), ASX -0.9% (Dec sales)
Other news:
  • IGMS -67.4% (Provides Strategic Update on Autoimmunity Pipeline Programs)
  • DYN -5.7% (reports new clinical data showing compelling impact on multiple measures of myotonic dystrophy type 1; Dyne plans to initiate registrational expansion cohort to support potential submission for u.s. accelerated approval for DYNE-101 in DM1 in H1 2026)
  • AMLX -4.8% (proposes offering of common stock)
  • YMAB -4.5% (provides strategic business update and 2025 priorities)
  • NKTR -4.4% (Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis)
  • CTNM -2.7% (completes enrollment in Phase 2 PIPE-307 VISTA trial)
  • EIX -2.7% (provides update on Southern California wildfires and SCE power outages)
  • AMD -1.9% (Biden plans additional round of restrictions on AI chip exports, according to Bloomberg)
  • NTLA -1.9% (Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran)
  • NVDA -1.5% (Biden plans additional round of restrictions on AI chip exports, according to Bloomberg)
  • OMAB -1.3% (Dec traffic)
  • BAM -1.1% (announces renewal of normal course issuer bid)
  • NGD -1.1% (reports record gold production in Q4)
  • MODV -1.1% (raises $105 million in incremental financing backed by stakeholders across the capital structure and takes strategic steps to position business for the future; withdraws guidance)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • PENG +15.6%, WBA +10.5%, ARHS +9.3% (guidance and CFO resignation), BBCP +8.8%, XERS +8.6% (guidance), ATRO +7.4% (guidance), BCRX +6.5% (guidance), DAL +6.3%, BDSX +4.7% (guidance), GMED +4%, GBX +1.6%, TSM +0.9% (Dec sales)
Other news:
  • AKYA +63.2% (confirms it is to be acquired by Quanterix Corporation)
  • DTIL +31.6% (Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency)
  • DBVT +16.7% (results from EPITOPE Phase 3 study)
  • ABOS +14.7% (announces journal of prevention of alzheimer's disease publication of the company's phase 1 intercept-ad study, including target engagement, dosing regimen and safety findings)
  • MRAM +14.4% (appoints new CFO)
  • CEG +9.5% (confirms plans to acquire Calpine at an equity purchase price of approximately $16.4 billion)
  • ZNTL +9% (announces azenosertib fast track designation and virtual corporate event to present updated data from azenosertib clinical studies)
  • QTRX +8.8% (completed the acquisition of Emission pursuant to Dec 16 Share Purchase Agreement)
  • CCO +7.9% (to sell its Europe-north segment to a subsidiary of Bauer Media Group for $625 mln)
  • ITOS +7.4% (outlines business updates and strategic priorities for 2025)
  • CVEO +7.1% (receives Civeo receives six-year contract extension from leading resource player)
  • TUYA +6.3% (Hosts Successful 'Tuya Developer Day' During CES 2025, Leading Industry Change with Innovative AI Technology)
  • CMPS +6% (announces the pricing of an underwritten offering of 24,014,728 American Depositary Shares and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs)
  • FVR +5.9% (REIT provides Q4 business update)
  • W +4.9% (announced its decision to exit the German market, effective immediately)
  • TLSI +4.6% (announces publication of pre-clinical data demonstrating improved delivery of Embospheres)
  • RIGL +4.1% (R289 granted orphan drug designation by the FDA for MDS)
  • RPRX +4% (announces two major steps to enhance shareholder value; raises dividend by 5%)
  • ABVX +3.9% (Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment)
  • ZLAB +3.9% (forms strategic partnership with MediLink Therapeutics to develop a novel LRRC15 antibody-drug conjugate)
  • PECO +3.2% (extends maturity of upsized revolving credit facility)
  • SPHR +3% (appoints new CFO)
  • APD +2.7% (issues response to Mantle Ridge; sends letter to shareholders correcting Mantle Ridge's falsehoods and misleading claims)
  • LUV +2.5% (CFO to retire April 1)
  • PLYM +2.5% (reports Q4 activity update)
  • QBTS +2.3% (CEO Dr. Alan Baratz Addresses NVIDIA CEO Jensen Huang's Quantum Comments on CNBC's "The Exchange"; announces that fiscal year 2024 bookings will exceed $23 million, an increase of approximately 120% over fiscal year 2023 bookings)
  • NVO +2.2% (Coave Therapeutics secures €32 million ($33 million) in series A financing to advance its next-generation genetic medicines)
  • IPHA +2.2% (Announces Transformative Strategy to Accelerate Growth)
  • TGB +1.9% (announces 2024 production results)

>>> Europe : Brokers Upgrades & Downgrades - 10th of January 2025 V3(++)

>>> Up
* Aedifica Raised to Buy at Bank Degroof Petercam (++)
* Alcon AG Raised to Buy at Redburn; PT 93 Swiss francs
* Amadeus Raised to Buy at UBS (+)
* AMS-Osram Raised to Hold at Kepler Cheuvreux (+)
* Antofagasta Raised to Equal-Weight at Morgan Stanley
* Atlas Copco Raised to Outperform at Handelsbanken; PT 260 kronor (+)
* Deutsche Telekom Raised to Buy at UBS; PT 33 euros
* DSM-Firmenich Raised to Outperform at BNPP Exane; PT 128 euros
* FLSmidth Raised to Neutral at Goldman; PT 375 kroner
* Gilead Raised to Overweight at Morgan Stanley; PT $113
* Hannover Re Raised to Outperform at BNPP Exane; PT 285 euros
* Legrand Raised to Buy at Kepler Cheuvreux (+)
* NXP Semi Raised to Buy at Goldman; PT $257
* Persimmon Raised to Buy at UBS as Selloff Overdone (+)
* Redcare Pharmacy NV Raised to Buy at mwb research AG (++)
* Reckitt Raised to Overweight at Morgan Stanley; PT 5,500 pence
* Snowflake Raised to Overweight at Barclays; PT $190
* UnitedHealth Raised to Buy at HSBC; PT $595
* Vinci Raised to Outperform at BNPP Exane; PT 121 euros
* Warehouse Raised to Buy at Shore Capital (+)
* WDP Raised to Buy at Bank Degroof Petercam (++)
* Xior Raised to Buy at Bank Degroof Petercam (++)
* YPF ADRs Raised to Overweight at JPMorgan; PT $59.50

>>> Down
* Aena Cut to Neutral at Citi; PT 210 euros
* AMD Cut to Neutral at Goldman; PT $129
* Croda Cut to Equal-Weight at Morgan Stanley; PT 3,700 pence
* Direct Line Cut to Hold at Deutsche Bank; PT 275 pence (+)
* E.On Cut to Neutral at BofA (+)
* Enagas Cut to Underperform at BofA (+)
* Greggs PT Cut to 2,000 pence from 2,400 pence at Deutsche Bank (+)
* Haleon Cut to Equal-Weight at Morgan Stanley; PT 410 pence
* Haleon ADRs Cut to Equal-Weight at Morgan Stanley; PT $10.20
* InterContinental Hotels Cut to Market Perform at Bernstein (+)
* Montea Cut to Hold at Bank Degroof Petercam (++)
* ON Semi Cut to Hold at Truist Secs; PT $60
* Scor Cut to Neutral at BNPP Exane; PT 26 euros
* Serco Cut to Hold at Jefferies; PT 175 pence
* Sodexo Cut to Market Perform at Bernstein (+)
* Tele2 Cut to Sell at UBS (+)
* Wacker Chemie Cut to Hold at Stifel; PT 77 euros

>>> Initiation
* BioNTech ADRs Rated New Buy at Truist Secs; PT $172
* Liontrust Rated New Underperform at RBC; PT 390 pence
* Polar Capital Rated New Outperform at RBC; PT 600 pence
* Semperit Rated New Buy at M.M. Warburg; PT 17.50 euros (+)
* SIG Group Rated New Overweight at Morgan Stanley

>>> Call
* Antofagasta Gains as Morgan Stanley Raises on Better Risk-Reward (++)
* Barclays Cau Warns of More Rates-Led Risk for UK Equities (++)
* Citi’s Manthey Expects Global Stocks to Rally 10% This Year (+)
* *CITI STRATEGISTS RAISE GLOBAL HEALTH CARE STOCKS TO OVERWEIGHT
* E.On, Enagas Shares Drop After BofA Cuts Recommendations (++)
* Haleon Falls; Morgan Stanley Sees Less Scope for Outperformance (++)
* MTG Gains as Kepler Cheuvreux Hikes PT; Sees Poor Valuation (++)
* Novo Rises After Goldman, Deutsche Bank Reaffirm Buy Ratings (++)
* Reckitt Hits Two-Month High; MS Upgrades on Re-Rating Potential (++)
* Serco Slides; Jefferies Cuts on Headwinds to Earnings Momentum (++)
* Sodexo Slips as Bernstein Downgrades on Guidance; IHG Cut (++)
* UBS Cuts Tele2, Lifts Deutsche Telekom: Europe Research Digest (++)
* Wacker Chemie Hits 2020-Low as Stifel Cuts, Sets Street-Low PT (++)

Linforme : Chauffage, climatisation... la famille Hermès et ICG en passe d’inves

Chauffage, climatisation... la famille Hermès et ICG en passe d’investir dans Climater
Trois ans après l’arrivée de la holding Cobepa, l’entreprise va à nouveau changer de mains, tout en faisant décoller très sensiblement sa valorisation.

Krefeld, la structure d’investissement créée par la famille Hermès pour cibler des entreprises non cotées, est en bonne voie de boucler une troisième emplette un an à peine après son lancement. À l’automne 2023, elle avait déjà investi aux côtés de KKR dans le façonnier cosmétique Anjac. Peu après, elle avait officialisé une prochaine prise de participation dans la compagnie d’assurances Albingia. Mais selon nos informations, la holding est aussi en bonne voie d’investir dans Climater, un installateur et réparateur de systèmes de climatisation et de chauffage très présent dans la moitié sud de la France et en région parisienne. Krefeld n’interviendra pas seul, puisque le family office partagera le contrôle de l’entreprise avec le fonds britannique ICG qui entre au capital dans le même temps. La holding CNP, une structure affiliée aux héritiers d’Albert Frère, prendra aussi quelques pourcents, et Sagard restera actionnaire. Quant au binôme de dirigeants, Stéphane Gillet et Marc Trouchaud, il conservera une part importante des parts, suivi par plusieurs centaines de collaborateurs de leur groupe.

Climater est aujourd’hui contrôlé par Cobepa, la holding d’investissement de la famille belge De Spoelberch (actionnaire historique du brasseur AB Inbev). Cette structure est propriétaire du prestataire de génie climatique depuis 2022 et une opération de LBO bouclée pour un montant de 350 millions d’euros. Selon une source, l’arrivée de Krefeld et d’ICG fera décoller la valorisation du groupe à près de 750 millions d’euros. Cette progression suit la croissance de son Ebitda, qui ressortirait actuellement à environ 65 millions d’euros contre un peu moins de 30 millions d’euros juste avant l’arrivée de Cobepa. La nouvelle opération de LBO reposera sur un financement bancaire mis en place par Crédit Agricole CIB. Edmond de Rothschild, Eight Advisory et Kearney ont épaulé la direction de Climater dans la préparation de cette opération.

Concurrent de Spie et d’Equans (filiale de Bouygues), Climater intervient à 70 % sur des projets de rénovation et travaille autant pour les milieux industriels que les logements sociaux. A titre d’exemple, il intervient historiquement sur des sites d’Airbus ou de Pierre Fabre nécessitant d’être maintenus sous température dirigée. « Le succès de cette entreprise repose sur sa capacité à prioriser son implantation sur des bassins d’emplois jouissant d’une certaine croissance démographique, même légère, souffle un connaisseur de l’entreprise. C’est là que les besoins en infrastructures sont les plus solides, et cela représente autant d’opportunités de contrats. » Le prestataire bénéficie par ailleurs du durcissement de la réglementation en matière de performance énergétique. Climater est surtout présent dans l’Hexagone mais le groupe a profité de ces dernières années pour s’implanter sur le marché canadien et envisage aujourd’hui de s’attaquer aux pays limitrophes de la France, notamment la Belgique, l’Allemagne et l’ Italie. Il ambitionne par ailleurs de se développer dans le domaine de la protection incendie (où il a réalisé une petite acquisition en 2024) et dans le génie électrique.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • DTIL +32.9%, DBVT +25.8%, MRSN +23.1%, ABOS +17.6%, PENG +17.5%, MRAM +14.4%, CCO +12.2%, DYN +11.7%, BBCP +10.8%, ARHS +9.6%, ZNTL +7.9%, CVEO +7.1%, QBTS +6.8%, TUYA +6.6%, FVR +5.9%, RAPP +5.4%, TLSI +4.6%, DAL +4.5%, RIGL +4.1%, QTRX +4.1%, ABVX +3.9%, ZLAB +3.9%, PECO +3.2%, RKLB +3.1%, SPHR +3%, NVO +2.9%, TGB +2.8%, GMED +2.8%, NVX +2.6%, COST +2.5%, SCM +2.5%, IPHA +2.2%, GBX +2.2%, BDSX +2%, NGD +1.8%, CURB +1.7%, APD +1.7%, TSM +1.6%, LUV +1.5%, PBR +1.5%, HNST +1.1%, CORZ +1.1%, CVX +1.1%, CNQ +1.1%, GMRE +1%, DNUT +1%, PSNY +0.9%, SNY +0.8%
  • Gapping down:
    • IGMS -68.7%, AVDL -26%, IMOS -7.9%, PSMT -5.1%, AMLX -4.8%, MODV -4.6%, NTLA -3.5%, GATO -2.8%, CTNM -2.7%, JEF -2.7%, EIX -2.4%, RPRX -1.9%, WSC -1.8%, AMD -1.7%, NHI -1.3%, BAM -1.1%, OMAB -1.1%

The Information : Wiz Completes Piece of IPO Puzzle

Wiz Completes Piece of IPO Puzzle

Five-year-old Wiz, a $16 billion–valuation startup that sells cloud cybersecurity software to large companies, has always had a flair for the dramatic. A few years ago, CEO Assaf Rappaport declared it the fastest-growing software company ever. In 2023, it openly mulled a takeover of larger, publicly held SentinelOne. And last year Wiz told its employees it was turning down a $23 billion acquisition offer from Alphabet—a rich offer to reject.

So maybe that’s why Wiz’s appointment Thursday of a chief financial officer with an unusual Hollywood-focused background feels fitting for one of the most closely watched private tech firms. Tel Aviv–based Wiz plucked Fazal Merchant out of a snowboarding-filled, Utah-based retirement, after a monthslong effort to find the right person for the job. Merchant, who has worked in various finance roles at investment banks, DirecTV and once-hot cybersecurity startup Tanium, also was CFO at Jeffrey Katzenberg’s DreamWorks.

In a phone interview Wednesday, Merchant, who is 51, acknowledged his unusual path. “If you look at my background, some would describe peculiar experiences. Maybe I’m struggling with professional ADD, I’m not sure,” he said, adding that he had been “living his best life” in retirement and wasn’t looking for a new gig when he connected with Wiz last year.

He said he was drawn to the company’s potential and will spend significant time at its U.S. outpost in New York. A big part of his job will be helping Wiz prepare for an initial public offering within the next year or so—a duty he’s never taken on before. “This team’s already broken records and milestones and [had] blinding growth,” he said.

Wiz also has been more blindingly candid about its IPO ambitions than most startups. Executives have said the company hopes to hit about $1 billion in annual recurring revenue before going public within the next year or so. Merchant said the number was “ambitious” but the company had “good visibility to [it].”

That target implies high growth, given that I’ve heard Wiz expects to finish this fiscal year, which ends this month, with more than $600 million in ARR. Another potential issue for IPO investors: The company still burns cash, although it’s unclear exactly how much. (A Wiz spokesperson declined to comment.)

On the positive side: Investors tend to like how many big company clients Wiz has managed to snag (45% of the Fortune 100, its website declares), and how much customers have continued to spend.

Still, Merchant’s hiring is an important puzzle piece in the late-2025 and 2026 venture-backed IPO slate. By my count, Wiz was one of the last major venture capital–backed IPO contenders without a CFO, after software firm Canva and artificial intelligence infrastructure startup Vast Data made their own appointments in recent months. Navan and CoreWeave, both of which are expected to go public this year, made their CFO hires last year, too.

Having a CFO is a necessary but not sufficient condition for a company to go public. Wiz will need to be sure it can confidently forecast to investors how fast it will grow each quarter, which is “challenging at this scale and this stage of growth,” Merchant said.

“I have a fair bit of work to do in terms of operations side—systems, governance, processes, controls,” Merchant added. “None of that is rocket science.”

An IPO, of course, is in part about storytelling, not just hard, cold numbers. Cybersecurity companies in particular care deeply about perception. Wiz has been more than capable of weaving a tale to private investors and the press for why it will be an important company. Soon it will have to tell that story to a bigger crowd.

>>> Europe : Brokers Upgrades & Downgrades - 10th of January 2025 V2(+)

>>> Up
* Alcon AG Raised to Buy at Redburn; PT 93 Swiss francs
* Amadeus Raised to Buy at UBS (+)
* AMS-Osram Raised to Hold at Kepler Cheuvreux (+)
* Antofagasta Raised to Equal-Weight at Morgan Stanley
* Deutsche Telekom Raised to Buy at UBS; PT 33 euros
* DSM-Firmenich Raised to Outperform at BNPP Exane; PT 128 euros
* FLSmidth Raised to Neutral at Goldman; PT 375 kroner
* Gilead Raised to Overweight at Morgan Stanley; PT $113
* Hannover Re Raised to Outperform at BNPP Exane; PT 285 euros
* Legrand Raised to Buy at Kepler Cheuvreux (+)
* NXP Semi Raised to Buy at Goldman; PT $257
* Persimmon Raised to Buy at UBS as Selloff Overdone (+)
* Reckitt Raised to Overweight at Morgan Stanley; PT 5,500 pence
* Snowflake Raised to Overweight at Barclays; PT $190
* UnitedHealth Raised to Buy at HSBC; PT $595
* Vinci Raised to Outperform at BNPP Exane; PT 121 euros
* Warehouse Raised to Buy at Shore Capital (+)
* YPF ADRs Raised to Overweight at JPMorgan; PT $59.50

>>> Down
* Aena Cut to Neutral at Citi; PT 210 euros
* AMD Cut to Neutral at Goldman; PT $129
* Croda Cut to Equal-Weight at Morgan Stanley; PT 3,700 pence
* Direct Line Cut to Hold at Deutsche Bank; PT 275 pence (+)
* E.On Cut to Neutral at BofA (+)
* Enagas Cut to Underperform at BofA (+)
* Greggs PT Cut to 2,000 pence from 2,400 pence at Deutsche Bank (+)
* Haleon Cut to Equal-Weight at Morgan Stanley; PT 410 pence
* Haleon ADRs Cut to Equal-Weight at Morgan Stanley; PT $10.20
* InterContinental Hotels Cut to Market Perform at Bernstein (+)
* ON Semi Cut to Hold at Truist Secs; PT $60
* Scor Cut to Neutral at BNPP Exane; PT 26 euros
* Serco Cut to Hold at Jefferies; PT 175 pence
* Sodexo Cut to Market Perform at Bernstein (+)
* Tele2 Cut to Sell at UBS (+)
* Wacker Chemie Cut to Hold at Stifel; PT 77 euros

>>> Initiation
* BioNTech ADRs Rated New Buy at Truist Secs; PT $172
* Liontrust Rated New Underperform at RBC; PT 390 pence
* Polar Capital Rated New Outperform at RBC; PT 600 pence
* Semperit Rated New Buy at M.M. Warburg; PT 17.50 euros (+)
* SIG Group Rated New Overweight at Morgan Stanley

>>> Call
* Citi’s Manthey Expects Global Stocks to Rally 10% This Year (+)
* *CITI STRATEGISTS RAISE GLOBAL HEALTH CARE STOCKS TO OVERWEIGHT

WSJ : Elon Musk’s xAI Launches Stand-Alone Grok App

Elon Musk’s xAI Launches Stand-Alone Grok App
Flagship AI chatbot was previously only available to X users


Elon Musk’s artificial-intelligence startup, xAI, launched its first stand-alone consumer app, its latest step as the company tries to catch up with more established players such as OpenAI and Google in the generative AI race.

The app is called Grok, which is also the name of the AI language model developed by xAI. Users noticed the app in Apple’s App Store early Thursday.

Previously, users could only access the Grok chatbot, xAI’s flagship product, through X, the social-media platform also run by Musk.

On Thursday, users were able to start using the new Grok app for free. There didn’t appear to be a subscription option in the version viewed by The Wall Street Journal.

Through the X platform, xAI rolled out a free version of the Grok chatbot last month, though the company said that X users who pay for Premium and Premium+ subscriptions would get higher usage limits.

The description in Apple’s App Store suggested the app was an early “beta” product and that it was being introduced to the U.S. “Introducing Grok Beta for iOS: get access to xAI’s latest model, Grok 2, for free,” it said.

Musk has declared xAI will create a less politically correct AI and has criticized competitors for being too “woke.” He has also sought to distinguish Grok by saying it has the advantage of access to up-to-date information via the X platform.

“Launching a stand-alone app gives it a chance to build a broader audience, beyond X users,” said Meghana Dhar, a former Snap and Instagram executive who is now a tech adviser.

While introducing a stand-alone app could also draw users away from X, Dhar said she didn’t think that was a major concern.

“I think there’s more stickiness to X users than that,” she said. “X users are very loyal to the platform.”

Musk launched xAI in 2023 to compete with OpenAI, the ChatGPT developer he co-founded but later left after a power struggle. Musk raced to recruit talent, raise billions of dollars from investors, and build a massive data center in Memphis, Tenn., to turn xAI into a competitive player in the AI industry.

xAI introduced the first version of its Grok chatbot four months after publicly launching the company in July 2023 and has released updated versions since.

The company has been working on other ways to generate revenue. Late last year, xAI released a paid tool developers can use to build products using Grok, offering discounts for early users.